Dr Jenny Harry – Chief Executive Officer
Jenny Harry has 20 years experience in executive management, securing global partnerships, commercialising technologies and raising capital. In her previous role, as CEO and Managing Director of Tyrian Diagnostics (ASX:TDX), Jenny transformed the company from an R&D business to a diagnostics company, and oversaw development of the company’s first diagnostic products through to commercialisation and early revenue generation. Jenny’s corporate experience extends to leading companies in the biotechnology and biopharmaceutical sectors with expertise in creating effective organisation structures, building high performing teams, strategic planning, and negotiating with multi-national corporations on the development and commercialisation of products.
Jenny received a PhD in developmental biology from Macquarie University, Sydney, and is a graduate of the Harvard Business School General Manager Program and the Australian Institute of Company Directors. In addition to her role as Managing Director at Ondek®, Dr Harry is a non-executive director on several boards, including Chair of QUT Enterprise Holdings Pty Ltd and a non-executive director on the board of ASX-listed Neuren Pharmaceuticals.
Dr Barry Marshall – Scientific Director
Professor Marshall is a world authority on Helicobacter pylori. He is the co-discoverer that H. pylori plays a major causative role in peptic ulcer diseases and co-recipient of the 2005 Nobel Prize for Physiology or Medicine as well as numerous other prestigious awards (including the 1995 Lasker Award). Professor Marshall was elected as a Fellow of the Royal Society in 1999 and the US National Academy of Sciences in 2008. He is one of the most esteemed and pre-eminent biomedical scientists in the world today. His discovery has revolutionised the management of peptic ulcer disease, resulting in a cure for peptic ulcers. Related research into a diagnostic test for H. pylori led to a patentable technology and the formation of TriMed Distributors Pty Ltd, a successful private company.
Dr Marshall is the founder of Ondek®. He is also a Clinical Professor at the University of Western Australia and a practising specialist gastroenterologist.
Dr Alma Fulurija – Head of Immunology and Translational Research
Dr Fulurija is an Australian graduate from Perth, attracted back from Switzerland after a successful career in the fields of novel vaccines and immunology. She has a wide variety of experience in vaccine development and immunotherapy including most recently with Cytos Biotechnology, voted Switzerland’s most exciting new biotechnology start-up float in 2005. She has also worked at the WHO Centre for Neonatal Immunology and Vaccinology in Geneva and has collaborated with Novartis and Pfizer on a number of projects. Dr Fulurija is an immunologist with expertise in translation of research to the clinic, with expertise in in vivo pre-clinical models and clinical and regulatory requirements for Phase I/II clinical trials. Dr Fulurija is Ondek’s Head of Immunology and Translational Reaearch and also holds an Adjunct Senior Lecturer position at the University of Western Australia.
Dr Senta Walton – Senior Immunologist
Dr Walton has considerable research experience in the field of immunology with a particular focus on the immune system in the context of chronic infection. She holds a PhD in biology from the Federal Institute of Technology in Zurich, Switzerland. In 2010 she received a research fellowship from the Swiss National Science Foundation to join Professor Barry Marshall’s group and study immune responses to H. pylori infection. She was subsequently awarded an NHMRC early career fellowship to continue her work in Australia. Her research projects have focused on how H. pylori infection modulates the host’s immune system through the characterisation of cellular immune responses in vitro and in vivo. Dr Walton is the Senior Immunologist at Ondek® and has oversight of many of the research activities associated with Ondek’s immunotherapy programme.
Dr Andy Herbert – Head of Pharmaceutical Operations
Andy Herbert has more than 30 years experience in the development and commercialization of products manufactured using various biotechnologies. After receiving a doctorate in biochemical engineering in 1984, sponsored by Unilever, he worked for five years in process development in ICI’s industrial fermentation and biochemicals division in the UK. He moved to Canada in 1989 and spent nine years with Sanofi-Pasteur, ultimately taking responsibility for all vaccine development at the Canadian site. He was part of teams that developed and licensed a highly effective acellular pertussis vaccine and the human cancer vaccine ImmuCyst® (for the treatment of superficial bladder cancer). In 1998 he founded a biopharmaceutical engineering consulting company in Toronto and over the next eight years built a team which has assisted more than 30 different biotechnology client companies in Canada, USA, Mexico, Cuba and Argentina. After moving to New Zealand in 2005, he has undertaken senior roles with ICPbio (biochemicals), Nutrizeal (nutraceuticals), BioPharmaceuticals Australia (mammalian cell culture facilities) and PolyBatics (nanoparticles manufactured in bacteria). He brings to Ondek® an in-depth knowledge of the stages and challenges involved in taking a product from an R&D environment to becoming a licensed, commercial biopharmaceutical.
Andy holds a PhD in biochemical engineering from University College London (University of London) and a BSc in biochemistry from University of Bath, UK. He is Chairman of NZBIO and on the board of BioProcessing Network Australia.